Change in volumes and radiation doses of parotid and submandibular glands during intensity modulated radiation therapy (IMRT) for nasopharyngeal carcinoma by Kwong, DLW et al.
Title
Change in volumes and radiation doses of parotid and
submandibular glands during intensity modulated radiation
therapy (IMRT) for nasopharyngeal carcinoma
Author(s) Lee, V; Ng, SCY; Kwong, DLW; Ho, PPY; Leung, TW; Au, GKH
Citation
The 53rd Annual Meeting of the American Society for Radiation
Oncology (ASTRO 2011), Miami, FL., 2-6 October 2011. In




Rights Radiation Oncology. Copyright © BioMed Central Ltd.
Proceedings of the 53rd Annual ASTRO Meeting S509modulated radiation therapy (IMRT) may improve the therapeutic ratio by reducing doses to normal tissue. The aim of this study
is to address the efficacy and toxicity profile of 3D-CRT including IMRT for a cohort of patients with locally recurrent NPC.
Materials/Methods:BetweenMay 1997 and June 2009, 212 patients diagnosed with locally recurrent NPC by biopsy and/or CT/
MRI evidence of progressive skull base erosion and clinical symptoms were treated with 3D-CRT or IMRT. Median time to re-
currence was 29 months (range 1 - 238 months) after the completion of conventional radiation to definitive dose. Fifty-three per-
cent of the cases had rT3 - 4 classification. Minimum planned doses were 50 - 60 Gy in 1.8 - 2 Gy per daily fraction to the gross
disease with margins, with or without chemotherapy.
Results: The median dose to the recurrent tumor was 64.2Gy (range 30 - 82Gy). Eleven patients received less than 50 Gy because
of the severe acute side-effects, 57 patients received 50 - 60Gy. With a median follow-up of 25 months (range 3 - 135months), the
locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) rates at 1-,3-,and 5 years
were 79.1%, vs. 43.7% vs. 30.6%, 78.8% vs. 43.1% vs. 29.6% and 79.1% vs. 44.5% vs. 31.9%, respectively. Moderate to severe
late toxicities were noted in 84 patients (39.6%), 24 patients (11.3%) had posterior nasal space ulceration, 38 (17.9%) developed
cranial nerve palsies, 28 (13.2%) had trismus, and 32 (15.1%) suffered deafness. Advanced recurrent T- classification and long
disease-free interval were adverse prognostic factors in multivariate analysis.
Conclusions: Re-irradiation with 3D-CRT provides reasonable long-term control in patients with locally recurrent NPC with ac-
ceptable profile of adverse-effects.
Author Disclosure: S.F. Qiu: None. J.D.J. Lu: None. S.J. Lin: None. I.W.K. Tham: None. J. Lu: None. J.J. Pan: None.2625 Treatment Outcome and Prognostic Factors for Nasopharyngeal Carcinoma with Cranial Nerve Palsy
Treated by Conventional or Conformal RadiotherapyC. Huang, E. Huang, C. Wang, H. Chen, H. Hsu, Y. Huang, C. Wang, Y. Wang, F. Fang
Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan
Purpose/Objective(s): To evaluate the therapeutic outcome for nasopharyngeal carcinoma (NPC) with cranial nerve (CN) palsy
treated by conventional or conformal radiotherapy (RT), and to analyze the associated prognostic factors.
Materials/Methods: A total of 104 patients with NPC with CN palsy curatively treated by conventional (n = 44) or conformal
(n = 60) RT from January 2000 to July 2007 were enrolled. Upper CN (II-VI) palsy was presented in 81 (78.9%) patients, lower
CN (VII-XII) palsy in 4 (3.8%) patients, and both upper and lower in 19 (18.3%) patients. Sixty-three (60.6%) patients had CN
palsy for more than 2 months before diagnosis. The median dose of RT was 73.9 Gy (range, 64.8 - 86.4 Gy). Concomitant cis-
platin-based chemotherapy (C/T) was given to 78 (75%) patients.
Results: Complete recovery of CN palsy was observed in 74 patients (71.2 %). The interval of CN palsy more than 2
months before diagnosis was the independent adverse prognosticator for the CN recovery following treatment (43.9 %
versus 88.9 %, p \ 0.001). The actuarial 5-year loco-regional control (LRC), distant metastasis-free survival (DMFS),
and overall survival (OS) rates were 58.2 %, 62.2 % and 38.4 %, respectively. No significant prognosticator was found
for LRC. On the contrast, we observed patients with age $ 60 years, histology of WHO type I, and without receiving
C/T had poorer OS; those with histology of WHO type I had worse DMFS. We did not observe any significant difference
in the CN recovery, LRC, DMFS, and OS for patients treated by conventional versus conformal technique. However, sig-
nificant reduction of grade 3 or greater toxicities was found in those treated by conformal technique. (odds ratio = 0.25,
95 % confidence interval = 0.10 - 0.61).
Conclusions: The recovery of CN palsy, LRC, and survival in NPC patients with CN palsy did not significantly change with the
treatment evolution for conventional to conformal technique.
Author Disclosure: C. Huang: None. E. Huang: None. C. Wang: None. H. Chen: None. H. Hsu: None. Y. Huang: None. C. Wang:
None. Y. Wang: None. F. Fang: None.2626 Change in Volumes and Radiation Doses of Parotid and Submandibular Glands during Intensity
Modulated Radiation Therapy (IMRT) for Nasopharyngeal CarcinomaV. Lee, S. C. Y. Ng, D. L. W. Kwong, P. P. Y. Ho, T. Leung, G. K. H. Au
Queen Mary Hospital, Hong Kong, Hong Kong
Purpose/Objective(s): To investigate the changes in volumes and radiation doses to parotid and submandibular glands during
IMRT for nasopharyngeal carcinoma in an attempt to justify re-planning in the mid-course of IMRT to minimize radiation-
induced xerostomia.
Materials/Methods: 33 consecutive patients with stage III to stage IVB nasopharyngeal carcinoma (AJCC Staging Manual 6th
Edition) who received concurrent chemoradiation were included in this study. Computed tomography (CT) scans were performed
for IMRT planning purposes (PLCT) and at mid-course of IMRT (MCCT) with head and neck immobilized by the same thermo-
plastic cast. Volumes of parotid and submandibular glands were outlined in these two set of CT images. Treatment plans were
generated by planning systems for PLCT. PLCTof all patients were then co-registered with their correspondingMLCT. The treat-
ment plans for PLCT were then copied to MCCT preserving the same beam shapes, angles and energies of PLCT. Dose distri-
bution on MCCT was then re-calculated using this re-normalized plan so that differences in radiation dose will be due to
anatomical and positioning changes rather than differences in dose calculation algorithms. Volumes of parotid and submandibular
glands on PLCTand MCCT together with dosimetric parameters including D95, D50, D05, D01 and minimum, mean, maximum
doses were compared by paired sample t-tests.
Results: All 33 patients had their volumes of parotid and submandibular glands significantly reduced on MCCT (Table 1). The
minimum and mean doses, D50, D05 and D01 of both parotids were significantly increased during mid-course while there was no
difference of the dosimetric parameters of both submandibular glands before and during mid-course.
S510 I. J. Radiation Oncology d Biology d Physics Volume 81, Number 2, Supplement, 2011Conclusions:Themajor salivary glands shrank and the parotids received a higher radiation dose during IMRT for nasopharyngeal
carcinoma. This signifies that adaptive radiotherapy with re-planning should be seriously considered during course of IMRT as
normal organs can receive an unexpected higher dose leading to more profound complications.





(PLCT/MCCT) p-valueMean volume (cm3) 27.25/21.23 0.000 24.43/18.56 0.000 8.16/5.42 0.000 7.73/5.41 0.000Mean change (%) -22.09 -24.03 -33.58 -30.01Author Disclosure: V. Lee: None. S.C.Y. Ng: None. D.L.W. Kwong: None. P.P.Y. Ho: None. T. Leung: None. G.K.H. Au: None.2627 Dosimetric Evaluation Of Less-than-daily IGRT Regimens In The Treatment Of Nasopharyngeal
CarcinomaY. Yu1, A. L. Michaud1, R. Sreeraman1, T. Liu2, J. A. Purdy1, A. Chen1
1University of California Davis Cancer Center, Sacramento, CA, 2University of Mississippi Cancer Center, Jackson, MS
Purpose/Objective(s): For head and neck cancers, less-than-daily image guided radiotherapy (IGRT) has been proposed as an
alternative to daily IGRT as a means of reduce imaging dose while maintaining treatment accuracy. The aim of this study was to
determine the dosimetric effects of less-than-daily IGRT on tumor volumes and critical structures in the treatment of nasopha-
ryngeal cancer (NPC) with intensity-modulated radiotherapy (IMRT).
Materials/Methods: Positioning and dosimetric data were collected from 10 NPC patients treated with IMRT to a prescription
dose of 70 Gy to 95% of the PTV in 33 fractions, in accordancewith guidelines proposed by RTOG trial 0615. Using megavoltage
CT data obtained daily per a prospective institutional registry protocol, three less-than-daily IGRT regimens were hypothetically
simulated: (1) imaging on the first fraction only, (2) weekly imaging with 3mm action threshold, and (3) imaging on alternating
days. To evaluate the dosimetric effect of these less-than-daily IGRT regimens, we shifted the planned dose matrices according to
simulated positional errors, discounting changes in anatomy. The following daily and cumulative endpoints were then analyzed:
dose to 95% (D95) and 99% (D99) of the gross tumor volume (GTV), clinical target volume (CTV) and planning target volume
(PTV), as well as the maximum doses to the brainstem, spinal cord, optic nerves, and optic chiasm.
Results: Initial results (n = 5) suggested that D95 and D99 for the GTVand CTVs met the planned dose for all patients, regard-
less of IGRT regimen. For the GTV, daily D95\95% of the planned dose occurred 7%, 4% and 1% of the time for regimens 1, 2,
and 3; and daily D99\ 95% of the planned dose occurred 14%, 10% and 5% of the time, respectively. Similarly, for the CTV,
daily D95 and D99\95% of the planned dose occurred on 2%, 1% and 0%, and on 12%, 4% and 2% of fractions, respectively.
The cumulative dose to the spinal cord exceeded dose constraints in 20% of patients with the first IGRT regimen. Using sim-
ulated IGRT regimens 1, 2, and 3, the daily doses exceeded dose constraints on 12%, 21%, and 6% of fractions for the brain-
stem, 30%, 12%, and 7% of fractions for the spinal cord, 9%, 12%, and 3% of fractions for the chiasm, and 18%, 21%, and 12%
of fractions for optic nerves, respectively.
Conclusions: Planned dose objectives to the GTVand CTV were satisfied with each of the less-than-daily IGRT regimens, but cu-
mulative overdose to the brainstem, spinal cord andoptic nerveswere observedwith IGRTon thefirst fractionand IGRTweekly. IGRT
onalternating days eliminated cumulative overdose andminimized fractional overdose to the brainstem, spinal cord, optic chiasmand
optic nerves. This suggests that less-than-daily IGRTmaybe clinically acceptable, provided sufficient PTVmargins are incorporated.
Author Disclosure: Y. Yu: B. Research Grant; RSNA Medical student Grant. A.L. Michaud: None. R. Sreeraman: None. T. Liu:
None. J.A. Purdy: None. A. Chen: None.2628 Brachytherapy, a Highly Focused Technique for Applying High Booster Doses of Radiation. Question: Can
it be of Value in Reducing the Local Relapse Rate in Advanced Cancer of the Nasopharynx?P. C. Levendag1, F. Keskin-Cambay1, D. N. Teguh1, M. El-Gantiry2, M. A. Wildeman3, C. de Pan1, B. Vikram4,
M. Abdel-Wahab5, E. Rosenblatt6
1Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam 3075 EA, Netherlands, 2Data Center Cairo for the data Analysis of
Prospective Randomized Trial Advanced Cancer Nasopharynx., Cairo, Egypt, 3The Netherlands Cancer Institute- Antoni van
Leeuwenhoek Hospital, 1066 CX, Amsterdam, Netherlands, 4NIH, Washington, WA, 5Data Center Cairo for the Data Analysis
of Prospective Randomized Trial Advanced Cancer Nasopharynx, Cairo, Egypt, 6International Atomic Energy Agency, Applied
Radiation Biology and Radiotherapy Division of Human Health, Vienna, Austria
Purpose/Objective(s): Mainstay of treatment of NPC is Intensity Modulated Radiation Therapy (IMRT). Except for T1N0 tu-
mors, a dose of 70/2 Gy is given to the primary tumor and neck nodes, combined with concomitant chemotherapy (cCHT). How-
ever, particularly with advanced T-stages (T3,4), patients remain to fail locally. Thus applications of conformal boosts using RT
doses beyond 70 Gy, might be appropriate. To enable boosting by endocavitary brachytherapy (BT) in limited T-stages (T1,2N0),
a Nasopharyngeal Applicator (NA) was designed. Whether the NA is as effective in early (T1,2) as in more advanced T3,4 NPC
categories is the purpose of this investigation.
Materials/Methods: The database for advanced NPC stages T1,2N+ and T3,4N0,+ consists of patients treated by 70 Gy and BT
boost (B) in the ErasmusMC (Rotterdam, n= 94), by 70 Gy and cCHTin the AvL/NKI (Amsterdam, n= 89) (C), and according to
